CombiMatrix and Manhattan Labs Enter Strategic Partnership to Service NYC Metropolitan Area
13 Agosto 2013 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, and Manhattan Labs
jointly announced today that they have entered into a strategic
partnership under which Manhattan Labs will market and distribute
CombiMatrix microarray tests for the miscarriage management testing
market in the New York City metropolitan area. The partnership was
enabled by the announcement in late June that CombiMatrix
miscarriage management tests had received conditional approval from
the New York State Department of Health for testing on patient
samples within the state.
Manhattan Labs is a high-end, independent clinical laboratory
that serves the New York City metropolitan area. Women's health,
particularly obstetrics and reproductive issues, is one of
Manhattan Lab's specialties, noted Chief Executive Officer Ken
Cerney.
"Our goal is to be the premier, full-service independent
clinical laboratory in the New York City area," Cerney said. "Our
labs offer the highest quality testing for all patients and now we
have added a new focus on miscarriage management. We believe adding
the operational and analytical support of CombiMatrix will be
beneficial to our physician customers and their patients, and will
expand the breadth of services we provide. We also believe in the
growing importance and clinical advantages microarray testing
provides for appropriate patients and look forward to working in
partnership with CombiMatrix."
Miscarriage management testing, a subset of the overall prenatal
testing market, allows OB/GYN physicians and clinicians to better
determine if there is a genetic cause for a miscarriage or other
related events. As in other areas of prenatal genetic analysis,
microarray testing is believed by many to be the coming standard of
care as it identifies a greater number of possible genetic
abnormalities more accurately than traditional methods.
CombiMatrix President and Chief Executive Officer Mark McDonough
noted that this partnership with Manhattan Labs enables CombiMatrix
to broaden the geographic reach of its leading growth product into
the important New York metropolitan area. At the same time, the
partnership demonstrates that microarray testing is gaining
acceptance as a preeminent diagnostic in the field of high quality
women's health.
"Clinical data is showing that, in terms of women's health,
microarray testing is quickly becoming the standard of care for
miscarriage management testing," McDonough said. "For CombiMatrix,
our goal is to partner with the very best and most respected
independent labs around the country and we are excited to be
teaming up with such an important company as Manhattan Labs. Adding
its marketing and distribution support to our own internal sales
efforts promises to be very beneficial to our growth and
prosperity."
About Manhattan Labs
Manhattan Physicians Laboratories, LLC ("Manhattan Labs") was
founded in 2008 with the goal of creating the premier
service-oriented, high-quality independent clinical laboratory in
New York City and the surrounding tri-state area. Combining the
latest in clinical laboratory technology, personalized service,
exceptional turnaround time and easy-to-access results, Manhattan
Labs is continuing to elevate the standards and set a new benchmark
of service in the laboratory industry. www.ManhattanLabs.com
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care. CombiMatrix specializes in miscarriage analysis,
prenatal and pediatric healthcare, offering DNA-based testing for
the detection of genetic abnormalities beyond what can be
identified through traditional methodologies. CombiMatrix
performs genetic testing utilizing a variety of advanced
cytogenomic techniques, including microarray, standardized and
customized FISH, and high resolution karyotyping. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and
include, but are not limited to, statements regarding the
advantages and efficacy of CMA over standard
karyotyping. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results
to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties
referred to above include, but are not limited to: market
acceptance of CMA as a preferred method over karyotyping; the rate
of transition to CMA from karyotyping; our ability to successfully
expand the base of our customers and strategic partners, add to the
menu of our diagnostic tests in both of our primary markets,
develop and introduce new tests and related reports, optimize the
reimbursements received for our testing services, and increase
operating margins by improving overall productivity and expanding
sales volumes; our ability to successfully accelerate sales, allow
access to samples earlier in the testing continuum, steadily
increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets;
changes in demand for our future products; legislative, regulatory
and competitive developments; general economic conditions; and
various other factors. Further information on potential
factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in
other filings with the Securities and Exchange Commission. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason, except as required by
law.
CONTACT: CombiMatrix Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Investor Relations Contact:
John Baldissera
BPC Financial Marketing
Tel (800) 368-1217
For Manhattan Labs inquiries:
Laura Johnson
Manhattan Labs
212-874-0500
ljohnson@manhattanlabs.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024